These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 31555394)

  • 1. Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.
    Zarakas MA; Desai JV; Chamilos G; Lionakis MS
    Curr Fungal Infect Rep; 2019 Sep; 13(3):86-98. PubMed ID: 31555394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
    Chamilos G; Lionakis MS; Kontoyiannis DP
    Clin Infect Dis; 2018 Jan; 66(1):140-148. PubMed ID: 29029010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive Fungal Infection Complicating Treatment With Ibrutinib.
    Rajapakse P; Gupta M; Hall R
    Cureus; 2021 Jun; 13(6):e16009. PubMed ID: 34336499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019.
    Gold JAW; Tolu SS; Chiller T; Benedict K; Jackson BR
    Clin Infect Dis; 2022 Aug; 75(2):334-337. PubMed ID: 34893821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors.
    Jin Y; Xu Z; Yan H; He Q; Yang X; Luo P
    Front Pharmacol; 2020; 11():891. PubMed ID: 32595510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
    Maffei R; Maccaferri M; Arletti L; Fiorcari S; Benatti S; Potenza L; Luppi M; Marasca R
    Blood Rev; 2020 Mar; 40():100635. PubMed ID: 31699465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
    Brochard J; Morio F; Mahe J; Le Pape P; Guimard T; Mahe B; Leterrier M; Morrier M; Raffi F; Boutoille D
    Med Mal Infect; 2020 Nov; 50(8):742-745. PubMed ID: 32777360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fungal diagnosis: how do we do it and can we do better?
    Perfect JR
    Curr Med Res Opin; 2013 Apr; 29 Suppl 4():3-11. PubMed ID: 23621588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib.
    Stein MK; Karri S; Reynolds J; Owsley J; Wise A; Martin MG; Zare F
    World J Oncol; 2018 Apr; 9(2):62-65. PubMed ID: 29760835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors.
    Du J; Yan H; Xu Z; Yang B; He Q; Wang X; Luo P
    Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1311-1325. PubMed ID: 34743659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinase inhibitors for cancer alter metabolism, blood glucose, and insulin.
    Duggan BM; Marko DM; Muzaffar R; Chan DY; Schertzer JD
    J Endocrinol; 2023 Feb; 256(2):. PubMed ID: 36476560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors.
    Olaharski AJ; Gonzaludo N; Bitter H; Goldstein D; Kirchner S; Uppal H; Kolaja K
    PLoS Comput Biol; 2009 Jul; 5(7):e1000446. PubMed ID: 19629159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.
    Arthurs B; Wunderle K; Hsu M; Kim S
    Respir Med Case Rep; 2017; 21():27-29. PubMed ID: 28377877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fungal infections in lung transplantation.
    Samanta P; Clancy CJ; Nguyen MH
    J Thorac Dis; 2021 Nov; 13(11):6695-6707. PubMed ID: 34992845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules.
    Goebel GL; Qiu X; Wu P
    Trends Pharmacol Sci; 2022 Oct; 43(10):866-881. PubMed ID: 35589447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
    Reinwald M; Silva JT; Mueller NJ; Fortún J; Garzoni C; de Fijter JW; Fernández-Ruiz M; Grossi P; Aguado JM
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S53-S70. PubMed ID: 29454849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.
    Bhatti M; Ayton S; Michail O; Gollop ND; Ryding A; Rushworth S; Bowles K; Geisler T; Flather M
    Thromb Res; 2019 Jul; 179():64-68. PubMed ID: 31082751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.
    Little JS; Weiss ZF; Hammond SP
    J Fungi (Basel); 2021 Dec; 7(12):. PubMed ID: 34947040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
    Ghez D; Calleja A; Protin C; Baron M; Ledoux MP; Damaj G; Dupont M; Dreyfus B; Ferrant E; Herbaux C; Laribi K; Le Calloch R; Malphettes M; Paul F; Souchet L; Truchan-Graczyk M; Delavigne K; Dartigeas C; Ysebaert L;
    Blood; 2018 Apr; 131(17):1955-1959. PubMed ID: 29437588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
    Wu P; Nielsen TE; Clausen MH
    Drug Discov Today; 2016 Jan; 21(1):5-10. PubMed ID: 26210956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.